Antihemophilic Products

Size: px
Start display at page:

Download "Antihemophilic Products"

Transcription

1 Antihemophilic Products Factor VIII Only Advate Alphanate Eloctate Helixate FS Hemofil M Humate - P Koate - DVI Kogenate FS with Vial Adapter Kogenate FS with Bioset Monoclate - P NovoEight Recombinate Wilate Xyntha Xyntha Solofuse

2 Antihemophilic Products - Factor VIII Only asdhealthcare.com Product Advate Antihemophilic Factor Alphanate Contains von Willebrand Factor Eloctate Manufacturer Baxalta Inc. (800) baxalta.com advate.com Grifols (800) grifolsusa.com alphanate.com Biogen (855) eloctate.com myeloctate.com Indications Contraindications In adults and children with Hemophilia A: control and prevention of bleeding episodes; perioperative management; routine prophylaxis to prevent or reduce the frequency of bleeding. Advate is not indicated for the treatment of von Willebrand disease. Life-threatening hypersensitivity reactions, including anaphylaxis, to mouse or hamster protein or other constituents of the product (mannitol, trehalose, sodium chloride, histidine, Tris, calcium chloride, polysorbate 80, and/or glutathione) Control and prevention of bleeding episodes and perioperative management in adult and pediatric patients with Factor VIII (FVIII) deficiency due to hemophilia A. Surgical and/or invasive procedures in adult and pediatric patients with von Willebrand Disease (VWD) in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery Life threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components Adults and children with Hemophilia A (congential Factor VIII deficiency) for: control and prevention of bleeding episodes, perioperative management, routine prophylaxis to prevent or reduce frequency of bleeding episodes; Eloctate is not indicated for the treament of von Willebrand disease Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to ELOCTATE Product Source Recombinant Plasma Recombinant rfviiifc Labelling for Removal of Pathogenic Prions Viral Removal Half-Life Recovery Packaged Product Storage Storage After Reconstitution Stabilizer N / A Solvent-detergent treatment; immunoaffinity chromatography; cation exchange chromatography In patients >16 yrs: ± 4.15 hours; infants (1 month to <2 yrs): 8.86 ± 1.78; 2 to 5 yrs old: ± 1.94; 5 to 12 yrs old: ± 1.60; 12 to 16 yrs old: ± 3.72 hours In patients >16 yrs: 2.57 ± 0.53 IU / dl / IU / kg; infants (1 month <2 yrs): 1.96 ± 0.21; 2 to 5 yrs old: 2.05 ± 0.62; 5 to 12 yrs old: 2.21 ± 0.44; 12 to 16 yrs old: 2.26 ± 0.42 IU / dl / IU / kg Refrigerate at 2 8 C (36 46 F); RT 30 C (86 F) for 6 months; do not return to refrigerated temperature; Yes; manufacturing process includes steps that provide a reasonable assurance that low levels of a vcjd model agent, if present in the starting material, would be removed PEG fractionation, Affinity Chromatography and Salt precipitation 17.9 ± 9.6 hours in hemophilia A patients; 7.67 ± 3.3 hours for VWF: RCo in VWD patients; 21.6 ± 7.8 hours for FVIII: C in VWD patients 96.7 ± 14.5% (mean ± SD) hours in hemophilia A patients; 3.3 ± 1.5 (IU / dl) / (IU / kg) for VWF:RCo in VWD patients; 2.1 ± 0.6 (IU / dl) / (IU / kg) for FVIII:C in VWD patients 36 months, up to printed expiration date at 25 C (77 F); N / A Detergent treatment; 15 nm filtration Adults: 19.7 ± 2.3 hours; yrs: 16.4 ± 2.3 hours; 6-11 yrs: 14.6 ± 3.1 hours; 2-5 yrs: 12 ± 2.45 hours 2.26 IU / dl / IU / kg 2 8 C (36 F 46 F) refrigerate; RT 30 C (86 F) for 6 months; ; protect from light Use within 3 hours; do not store or refrigerate RT; use within 3 hours RT < 30 C; use within 3 hours In 5 ml reconstituted vial: Tris 10 mm, calcium chloride 1.7 mm, mannitol 3.2% (w / v), sodium chloride 90 mm, α, α-trehalose 0.8% (w / v), histidine 10 mm, glutathione (reduced) 0.08 mg / ml, polysorbate % (w / v); In 2 ml reconstituted vial: Tris 25 mm, calcium chloride 4.2 mm, mannitol 8% (w / v), sodium chloride 225 mm, α, α-trehalose 2% (w / v), histidine 25 mm, glutathione (reduced) 0.2 mg / ml, polysorbate % (w / v); the final product contains no more than 2 ng VWF / IU rahf, which will not have any clinically relevant effect in patients with von Willebrand disease Albumin added Diluent Volume 2 ml / 5 ml 5 ml / 10 ml 3 ml Sucrose, sodium chloride, L-histidine, calcium chloride and polysorbate 20 Available Sizes 250 / 500 / 1000 / 1500 / 2000 / 3000 / 4000 IU 250 / 500 / 1000 / 1500 / 2000 IU FVIII 250 / 500 / 750 / 1000 / 1500 / 2000 / 3000 IU Some products may be stored ambient. To help maintain product integrity, products will only be accepted for return when they are shipped according to the return guidelines of ASD Healthcare and the product s manufacturer.

3 Helixate FS CSL Behring (800) cslbehring-us.com helixatefs.com Control and prevention of bleeding episodes and peri-operative management in adults and children (0 16 years) with Hemophilia A; routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with Hemophilia A without pre-existing damage Hemofil M Antihemophilic Factor ( Human ), Method M, Monoclonal Purified Baxalta Inc. (800) baxalta.com Hemophilia A for the prevention and control of hemorrhagic episodes Humate-P Contains von Willebrand Factor CSL Behring (800) cslbehring-us.com humate-p.com Hemophilia A for treatment and prevention of bleeding in adult patients; von Willebrand disease for the treatment of spontaneous and trauma-induced bleeding episodes and prevention of excessive bleeding during and after surgery; not indicated for the prophylaxis of spontaneous bleeding episodes in VWD Life-threatening hypersensitivity reactions, including anaphylaxis to mouse or hamster protein or other constituents of the product Hypersensitivity to the active substance, to excipients, or to mouse proteins Anaphylactic or severe systemic reaction to antihemophilic factor or VWF preparations Recombinant Plasma Plasma N / A N / A N / A Solvent detergent; ion exchange chromatography; monoclonal antibody immunoaffinity chromatography Solvent-detergent treatment; immunoaffinity chromatography; nanofiltration Cryoprecipitation; Al(OH)3 adsorption, glycine precipitation, NaCl precipitation studied in combination; heat treatment at 60 C for 10 hours in aqueous solution; lyophilization ± 1.82 hours (adult); 10.7 hours (children) 14.8 ± 3 hours 12.2 hours; 10.3 hours von Willebrand disease 2.2 ± 0.34 IU / dl / IU/kg (adult); 1.9 IU / dl / IU / kg (children) 2.0 IU / dl / IU / kg 2 IU / dl / IU / kg von Willebrand disease RT 25 C (77 F) for 12 months; ; protect from light 2 C 8 C (36 F to 46 F); RT < 30 C (86 F), until expiration date noted on the package; Up to 36 months at 25 C (77 F); RT; use within 3 hours RT; use within 3 hours Use within 3 hours Sucrose; glycine; histidine Contains a maximum of 12.5 mg / ml Albumin and per AHF International Unit; 0.07 mg polyethylene glycol (3350) and 0.39 mg histidine Albumin added 2.5 ml / 5 ml 10 ml 5 ml / 10 ml / 15 ml 250 / 500 / 1000 / 2000 / 3000 IU approximate F VIII activity 250 / 500 / 1000 / 1700 IU 600:250 / 1200:500 / 2400:1000 RCoF:FVIII While every effort has been made to ensure the accuracy and completeness of the information presented, the author, editor, or publisher cannot be responsible for any errors or omissions. All provided information is obtained from FDA approved product information ASD Healthcare. Chart updated November 2015.

4 Antihemophilic Products - Factor VIII Only asdhealthcare.com Product Koate -DVI Kogenate FS with Bioset Kogenate FS with Vial Adapter Monoclate-P Manufacturer Kedrion BioPharma, Inc. (855) kedrion.com koate-dviusa.com Bayer Healthcare (888) bayerhealthcare.com kogenatefs.com Bayer Healthcare (888) bayerhealthcare.com kogenatefs.com CSL Behring (800) cslbehring-us.com Indications Hemophilia A, for temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or to perform emergency and elective surgery for patients with Hemophilia A Contraindications None Hypersensitivity to any components, mouse or hamster proteins Hemophilia A Hemophilia A Hemophilia A Hypersensitivity to any components, mouse or hamster proteins Hypersensitivity to mouse protein Product Source Plasma Recombinant Recombinant Plasma Viral Removal TNBP / polysorbate 80 treatment and dry heat Solvent detergent; ion exchange chromatography; monoclonal antibody immunaffinity chromatography Solvent detergent; ion exchange chromatography; monoclonal antibody immunaffinity chromatography Pasteurization; heat; precipitation Half-Life hours ± 2.62 hours ± 4.38 hours 17.5 hours Recovery 1.9% IU / kg 2.43 ± 0.60 IU / kg 2.11 ± 0.37 IU / kg 1.9 IU / dl / IU / kg Packaged Product Storage Storage After Reconstitution RT 25 C (77 F) for 6 months; RT 25 C for 12 months; ; protect from light 2 8 C (36 46 F) refrigerate for up to 30 months or expiration date; RT 25 C for 12 months or expiration date; ; protect from light; once stored at RT do not return to refrigeration RT 25 C (77 F) for 6 months; RT; use within 3 hours RT; use within 3 hours RT; use within 3 hours RT 37 C; use within 3 hours Stabilizer Glycine Sucrose; glycine; histidine Sucrose; glycine; histidine Albumin; no von Willebrand Factor Diluent Volume 5 ml / 10 ml 2.5 ml / 5 ml 2.5 ml / 5 ml 2.5 ml / 5 ml / 10 ml Available Sizes 250 / 500 / 1000 IU 250 / 500 / 1000 / 2000 / 3000 IU 250 / 500 / 1000 / 2000 / 3000 IU 250 / 500 / 1000 / 1500 IU approximate FVIII activity Some products may be stored ambient. To help maintain product integrity, products will only be accepted for return when they are shipped according to the return guidelines of ASD Healthcare and the product s manufacturer.

5 NovoEight Recombinate Antihemophilic Factor Wilate Contains von Willebrand Factor Xyntha Xyntha Solofuse Novo Nordisk (800) novonordisk-us.com novoeight.com Baxalta Inc. (800) baxalta.com recombinate.com Octapharma (888) octapharma.com wilateusa.com Pfizer Inc. (800) pfizer.com xyntha.com/solofuse Hemophilia A Hemophilia A for the prevention and control of hemorrhagic episodes; perioperative management von Willebrand disease in adult and pediatric patients for on-demand treatment and control of bleeding, and perioperative management of bleeding Hemophilia A Life-threatening hypersensitivity reactions, including anaphylaxis, to NovoEight or its components, including hamster proteins Life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including bovine, mouse or hamster proteins Hypersensitivity with known anaphylaxis or severe systemic reaction to human plasma-derived products, any ingredient in the formulation or components of the container Life-threatening hypersensitivity, including anaphylaxis, to the product or its components, including hamster proteins Recombinant Recombinant; human albumin added as a stabilizer & excipient, is from plasma Plasma Recombinant Detergent treatment; nanofiltration Immunoaffinity column chromatography; ion exchange chromatography Solvent detergent treatment; terminal dry heat 100 C for 120 minutes; ion exchange chromatography Affinity chromotography; solvent detergent viral inactivation step; virus-retaining nanofiltration step hours in adults 14.6 ± 4.9 hours VWF: 15.8 ± 11 hours; FVIII: 19.6 ± 6.9 hours (IU / ml) / (IU / kg) in adults ~2.0 IU / dl / IU / kg VWF: RCo: 1.9 ± 0.4% IU / kg; FVIII: C: 2.2 ± 0.5 IU / kg 2 8 C (36 F 46 F) refrigerate for up to 30 months from the date of manufacture until the expiration date; RT 30 C (86 F) for 12 months; ; store in original package to protect from light RT; use within 4 hours; store the reconsituted product in the vial Sodium chloride; sucrose; calcium chloride dihydrate RT 30 C (86 F); 2 8 C (36 F 46 F) for 36 months; RT<25 C (77 F) for 6 months; once stored at room temperature, the product must not be returned to the refrigerator; 11.8 ± 6.2 hours 2.47 ± 0.84 IU / dl / IU / kg RT 25 C for 3 months; ; protect from light RT; use within 3 hours Use immediately RT; use within 3 hours In 5 ml reconstituted vial: 25 mg / ml Albumin (human), 0.40 mg / ml calcium, 3 mg / ml polyethylene glycol (3350), 360 meq / L sodium, 110 mm histidine, 1.5 μg / Factor VIII IU polysorbate-80 In 10 ml reconstituted vial: 12.5 mg / ml Albumin (human), 0.20 mg / ml calcium, 1.5 mg / ml polyethylene glycol (3350), 180 meq / L sodium, 55 mm histidine, 1.5 μg / Factor VIII (IU) polysorbate-80; the final product for both diluent sizes contains not more than 2 ng rvwf / IU rfviii, which will not have any clinically relevant effect in patients with von Willebrand disease 4 ml sodium chloride diluent 5 ml / 10 ml 5 ml / 10 ml 4 ml N / A Sucrose; sodium chloride; L-histadine; calcium; polysorbate / 500 / 1000 / 1500 / 2000 / 3000 IU 250 / 500 / 1000 / 1500 / 2000 IU 500 / 1000 IU R2 Kit: 250 / 500 / 1000 / 2000 IU; Xyntha Solofuse: (dual chamber syringe) 250 / 500 / 1000 / 2000 / 3000 IU While every effort has been made to ensure the accuracy and completeness of the information presented, the author, editor, or publisher cannot be responsible for any errors or omissions. All provided information is obtained from FDA approved product information ASD Healthcare. Chart updated November 2015.

6 Antihemophilic Products - Factor VIII Only Others asdhealthcare.com aspire. ASD Healthcare delivers. When you re in the business of saving lives, you depend on exceptional customer service from your healthcare partners. So when you want a life-saving medication within hours, or need an extensive range of plasma-derived and recombinant therapeutics, connect with ASD Healthcare. Our people are here to help you get the products you need, when you need them. That s standard business for us, a part of our True Blue culture that makes going the extra mile an ordinary part of our day. Others aspire to meet our exceptional service. ASD Healthcare simply delivers. Convenient Connection ASD Healthcare makes it easy to order and reorder your inventory any time, any day, anywhere. Connect at Customer Service Emergency on-call phone orders 365 / 24 / 7 Expedited orders for same-day delivery in 48 states Expertise and resources for access to critical care products Your Patients. Your Purpose. Our Priority.

Clotting Disorder Therapy

Clotting Disorder Therapy Last Review Date: October 13, 2017 Number: MG.MM.PH.25b Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth

More information

Factor Replacement Products. Hem/Onc Fellows 2017

Factor Replacement Products. Hem/Onc Fellows 2017 Factor Replacement Products Hem/Onc Fellows 2017 Factor VIII concentrates: History and Current Issues 1950-1960 Fresh Frozen Plasma Mid 1960 Cryoprecipitate from FFP 1970s Lyophilized concentrates from

More information

CLOTTING FACTOR REPLACEMENT THERAPY

CLOTTING FACTOR REPLACEMENT THERAPY CLOTTING FACTOR REPLACEMENT THERAPY Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage

More information

CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS

CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS UnitedHealthcare Commercial Medical Benefit Drug Policy CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS Policy Number: 2018D0047K Effective Date: January 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE...

More information

Antihemophilic Factor (Recombinant BDD) Fc Fusion Protein (Eloctate): Treatment Cost Comparison and Budget Impact Analysis

Antihemophilic Factor (Recombinant BDD) Fc Fusion Protein (Eloctate): Treatment Cost Comparison and Budget Impact Analysis CADTH TECHNOLOGY REVIEW Antihemophilic Factor (Recombinant BDD) Fc Fusion Protein (): Treatment Cost Comparison and Budget Impact Analysis Product Line: Technology Review Version: 1.0 Issue Number: 2 Publication

More information

KOGENATE FS BAYER MIDDLE EAST

KOGENATE FS BAYER MIDDLE EAST 08-15 KOGENATE FS BAYER MIDDLE EAST Formulated with Sucrose DESCRIPTION is a sterile, stable, purified, nonpyrogenic, dried concentrate that has been manufactured using recombinant DNA technology. Kogenate

More information

Clotting Factors and Coagulant Blood Products

Clotting Factors and Coagulant Blood Products Clotting Factors and Coagulant Blood Products Policy Number: 5.02.520 Last Review: 04/2018 Origination: 04/2016 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide

More information

Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404

Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Clinical Policy: (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Effective Date: January 2008 Last Review Date: 12/16 See Important Reminder at the end of this

More information

PRINCIPLES OF CLOTTING FACTOR THERAPY IN HEMOPHILIA A and B

PRINCIPLES OF CLOTTING FACTOR THERAPY IN HEMOPHILIA A and B PRINCIPLES OF CLOTTING FACTOR THERAPY IN HEMOPHILIA A and B 2013 Carol K. Kasper, M.D. Hemophilia Treatment Center Los Angeles Orthopaedic Hospital 2400 South Flower Street Los Angeles, CA 90007 carolkasper@hotmail.com

More information

Longer acting/extended Half Life Products: Laboratory Monitoring

Longer acting/extended Half Life Products: Laboratory Monitoring Longer acting/extended Half Life Products: Laboratory Monitoring Steve Kitchen Lead Clinical scientist Sheffield Haemophilia Centre & UK NEQAS Blood Coagulation Declaration of Interests -1 Speaker/ consultancy

More information

MASAC RECOMMENDATIONS CONCERNING PRODUCTS LICENSED FOR THE TREATMENT OF HEMOPHILIA AND OTHER BLEEDING DISORDERS (Revised April 2010)

MASAC RECOMMENDATIONS CONCERNING PRODUCTS LICENSED FOR THE TREATMENT OF HEMOPHILIA AND OTHER BLEEDING DISORDERS (Revised April 2010) MASAC Document #195 (Replaces Document #190) MASAC RECOMMENDATIONS CONCERNING PRODUCTS LICENSED FOR THE TREATMENT OF HEMOPHILIA AND OTHER BLEEDING DISORDERS (Revised April 2010) The following recommendation

More information

RECOMBINATE. [Antihemophilic Factor (Recombinant)] DESCRIPTION. Lyophilized Powder for Reconstitution for injection

RECOMBINATE. [Antihemophilic Factor (Recombinant)] DESCRIPTION. Lyophilized Powder for Reconstitution for injection RECOMBINATE [Antihemophilic Factor (Recombinant)] Lyophilized Powder for Reconstitution for injection Reconstitute with 5 ml of Sterile Water for Injection using BAXJECT II DESCRIPTION RECOMBINATE [Antihemophilic

More information

ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] Safety and effectiveness: 10 years of clinical experience

ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] Safety and effectiveness: 10 years of clinical experience ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] Safety and effectiveness: 10 years of clinical experience Alfonso Iorio, MD, PhD Health Information Research Unit & Hemophilia Program

More information

Alphanate (Antihemophilic Factor/von Willebrand Factor Complex [Human])

Alphanate (Antihemophilic Factor/von Willebrand Factor Complex [Human]) Alphanate (Antihemophilic Factor/von Willebrand Factor Complex [Human]) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALPHANATE safely and effectively.

More information

Virus Safety in Plasma- Derived Therapeutics: A Merck Perspective. IPFA Yogyakarta, March Louis Wong

Virus Safety in Plasma- Derived Therapeutics: A Merck Perspective. IPFA Yogyakarta, March Louis Wong Virus Safety in Plasma- Derived Therapeutics: A Merck Perspective IPFA Yogyakarta, March 2017 Louis Wong Associate director, Plasma Initiative, Asia-Pacific Content Regulatory Expectations for Plasma-Derived

More information

PRODUCT MONOGRAPH ADVATE. Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (rahf-pfm)

PRODUCT MONOGRAPH ADVATE. Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (rahf-pfm) PRODUCT MONOGRAPH ADVATE Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (rahf-pfm) 250, 500, 1000, 1500, 2000 and 3000 International Units (IU) per vial Coagulant Manufactured by: Imported

More information

A. National Hemophilia Organization

A. National Hemophilia Organization A. National Hemophilia Organization Organization name Czech Society of Hemophilia City Prague Country Czechia Phone +420603580980 E-mail info@hemofilici.cz This form completed by: First name Vladimír Last

More information

Critical Quality Attributes for Blood Products. Tim Lee, Ph.D. OBRR/CBER/FDA 12 January 2009 WCBP

Critical Quality Attributes for Blood Products. Tim Lee, Ph.D. OBRR/CBER/FDA 12 January 2009 WCBP Critical Quality Attributes for Blood Products Tim Lee, Ph.D. OBRR/CBER/FDA 12 January 2009 WCBP 1 Disclaimer The views expressed during this presentation are my own and may not be those of the FDA 2 Blood

More information

Hemophilia A and B Recombinant Factor Replacement Therapy - 5EU Drug Forecast and Market Analysis to 2024

Hemophilia A and B Recombinant Factor Replacement Therapy - 5EU Drug Forecast and Market Analysis to 2024 Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Hemophilia A and B Recombinant Factor Replacement Therapy - 5EU Drug Forecast and Market Analysis to 2024 Hemophilia

More information

Biotechnology of Human Plasma-Derived Medicines in Scope of Collaboration Perspectives within The Central European Initiative

Biotechnology of Human Plasma-Derived Medicines in Scope of Collaboration Perspectives within The Central European Initiative Biotechnology of Human Plasma-Derived Medicines in Scope of Collaboration Perspectives within The Central European Initiative Dr Vadim Sentchouk PHARMLAND LLC Deputy General Director PLASMAPHARM LLC General

More information

Human Protein Process Sciences, Lille, France 2. Shabrawishi Hospital Blood Bank, Cairo, Egypt 3. University of Saskatoon, Canada

Human Protein Process Sciences, Lille, France 2. Shabrawishi Hospital Blood Bank, Cairo, Egypt 3. University of Saskatoon, Canada 1 Human Protein Process Sciences, Lille, France 2 Shabrawishi Hospital Blood Bank, Cairo, Egypt 3 University of Saskatoon, Canada Why such a concept? Non-virally inactivated plasma components are still

More information

International Society Laboratory Hematology Milan, May Current and Emerging Approaches for Assessing von Willebrand disease (VWD) in 2016

International Society Laboratory Hematology Milan, May Current and Emerging Approaches for Assessing von Willebrand disease (VWD) in 2016 International Society Laboratory Hematology Milan, 12-14 May 2016 Current and Emerging Approaches for Assessing von Willebrand disease (VWD) in 2016 Augusto B. FEDERICI Hematology and Transfusion Medicine

More information

A MANUFACTURING PROCESS TO OBTAIN A HIGHLY-PURIFIED TRIPLE-SECURED FIBRINOGEN PRODUCT

A MANUFACTURING PROCESS TO OBTAIN A HIGHLY-PURIFIED TRIPLE-SECURED FIBRINOGEN PRODUCT A MANUFACTURING PROCESS TO OBTAIN A HIGHLY-PURIFIED TRIPLE-SECURED FIBRINOGEN PRODUCT Maduell P, Domingo N, López L, Gensana M, Caballero S, Belda P, Gajardo R, Grancha S, Ristol P R&D Area, Instituto

More information

Hemophilia Care Delivery in 2016: New factors and beyond factors Where do we go from here?

Hemophilia Care Delivery in 2016: New factors and beyond factors Where do we go from here? Hemophilia Care Delivery in 2016: New factors and beyond factors Where do we go from here? Ellis J. Neufeld MD, PhD Medical Director, Boston Hemophilia Center Egan Family Foundation Professor, Harvard

More information

Hemophilia A and B Recombinant Factor Replacement Therapy - Argentina Drug Forecast and Market Analysis to 2024

Hemophilia A and B Recombinant Factor Replacement Therapy - Argentina Drug Forecast and Market Analysis to 2024 Hemophilia A and B Recombinant Factor Replacement Therapy - Argentina Drug Forecast and Market Analysis to 2024 Hemophilia A and B Recombinant Factor Replacement Therapy - Argentina Drug Forecast and Market

More information

Category Storage Shelf Life Additional Criteria

Category Storage Shelf Life Additional Criteria CE Update [blood banking/transfusion medicine] Blood Components for Hemostasis Jun Teruya, MD, DSc, and Glenn Ramsey, MD From the Department of Pathology, Northwestern University Medical School, Chicago.

More information

*Sections or subsections omitted from the full prescribing information are not listed

*Sections or subsections omitted from the full prescribing information are not listed HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Kogenate FS safely and effectively. See full prescribing information for Kogenate FS. Kogenate FS

More information

New Perspectives in Hemophilia Treatment

New Perspectives in Hemophilia Treatment New Perspectives in Hemophilia Treatment Craig M. Kessler A variety of factor concentrates are currently available for replacement therapy for patients with hemophilia. These differ by several parameters,

More information

PHARMA DEVELOPMENT DIGEST HEMOPHILIA A

PHARMA DEVELOPMENT DIGEST HEMOPHILIA A PHARMA DEVELOPMENT DIGEST HEMOPHILIA A Reprint from PDD Hematology April 2017 ANDERSON CONSULTING GROUP Overview Greylock Pharma Development Digest is a surveillance service designed for pharmaceutical

More information

Octapharma, a Swiss manufacturer

Octapharma, a Swiss manufacturer Parent Empowerment Newsletter LA Kelley Communications, Inc. inside 3 As I See It: Andy s Healthcare Cost Solution 4 Inhibitor Insights: Bypassing Agents: Which Product Is Better? 5 Transitions: Hemophilia

More information

Fractionation Services and Recombinant Plasma Protein Products: Product Supply and Transitioning

Fractionation Services and Recombinant Plasma Protein Products: Product Supply and Transitioning Frequently sked uestions and Recombinant Plasma Supply and Transitioning Summary of product changes Red (underlined): not continuing Blue (bold): new Today s Product Mix Future Product Mix Product Size

More information

Current and Emerging Treatment Paradigms in the Management of Hemophilia

Current and Emerging Treatment Paradigms in the Management of Hemophilia Current and Emerging Treatment Paradigms in the Management of Hemophilia Barbara A. Konkle, MD Associate Director, Washington Center for Bleeding Disorders Director, Clinical and Translational Research

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection

More information

Guideline on core SmPC for human fibrinogen products

Guideline on core SmPC for human fibrinogen products 23 July 2015 EMA/CHMP/BPWP/691754/2013 Rev 1 Committee for Medicinal Products for Human Use (CHMP) Draft Agreed by Blood Products Working Party 27 November 2013 Adoption by CHMP for release for consultation

More information

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION FIBRYGA

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION FIBRYGA PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION FIBRYGA Fibrinogen Concentrate (Human) Powder for Solution for Injection / Infusion, 1 g/vial ATC-Code: B02BB01 Manufactured by: Octapharma Pharmazeutika

More information

Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate

Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Application for retention on the WHO Model List From: Plasma Protein Therapeutics Association (PPTA) 1. Summary

More information

Laboratory Aspects of recombinant porcine FVIII and extended half life concentrates

Laboratory Aspects of recombinant porcine FVIII and extended half life concentrates Laboratory Aspects of recombinant porcine FVIII and extended half life concentrates Rajiv K. Pruthi, M.B.B.S Co-Director, Special Coagulation Laboratory & Director, Mayo Comprehensive Hemophilia Center

More information

IG Production and Safety

IG Production and Safety IG Production and Safety Platelet Disorder Support Association July 20, 2013 Mary Gustafson, Vice President, PPTA Global Regulatory Policy Presentation Outline Introduction - PPTA Plasma Collection Final

More information

Best camp ever! It s awesome. It s awesome.

Best camp ever! It s awesome. It s awesome. Fall 2013 Best camp ever! Best camp ever! This was the compliment heard most frequently at the awards ceremony on Thursday when parents came to pick up their campers after five days and four nights of

More information

Excipient Albumin CSL Behring Human Serum Albumin

Excipient Albumin CSL Behring Human Serum Albumin Excipient Albumin CSL Behring Human Serum Albumin For more information, contact CSL Behring USA: (610) 878-4000 1020 First Avenue King of Prussia, PA 19406-0901 Switzerland: +41 31 344 44 44 Wandorfstrasse

More information

GUIDE FOR THE ASSESSMENT OF CLOTTING FACTOR CONCENTRATES

GUIDE FOR THE ASSESSMENT OF CLOTTING FACTOR CONCENTRATES GUIDE FOR THE ASSESSMENT OF CLOTTING FACTOR CONCENTRATES 3 rd edition Prepared by Albert Farrugia, BSc, PhD for the World Federation of Hemophilia Published by the World Federation of Hemophilia (WFH)

More information

MASAC RECOMMENDATIONS CONCERNING PRODUCTS LICENSED FOR THE TREATMENT OF HEMOPHILIA AND OTHER BLEEDING DISORDERS (Revised August 2017)

MASAC RECOMMENDATIONS CONCERNING PRODUCTS LICENSED FOR THE TREATMENT OF HEMOPHILIA AND OTHER BLEEDING DISORDERS (Revised August 2017) MASAC Document #250 (Replaces Document #249) MASAC RECOMMENDATIONS CONCERNING PRODUCTS LICENSED FOR THE TREATMENT OF HEMOPHILIA AND OTHER BLEEDING DISORDERS (Revised August 2017) The document was approved

More information

Characterization of the Recombinant Human Factor VIII Expressed in the Milk of Transgenic Swine. William Anderson Hodges

Characterization of the Recombinant Human Factor VIII Expressed in the Milk of Transgenic Swine. William Anderson Hodges Characterization of the Recombinant Human Factor VIII Expressed in the Milk of Transgenic Swine William Anderson Hodges Thesis submitted to the faculty of the Virginia Polytechnic Institute and State University

More information

HERCEPTIN(R) Vials (150 mg)

HERCEPTIN(R) Vials (150 mg) Safety Data Sheet HERCEPTIN(R) Vials (150 mg) SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Product name Product code Synonyms HERCEPTIN(R) Vials

More information

Prion Removal Capacity of Plasma Protein Manufacturing Processes

Prion Removal Capacity of Plasma Protein Manufacturing Processes Prion Removal Capacity of Plasma Protein Manufacturing Processes 1 A data collection from PPTA member companies Presented by Nathan Roth, Ph.D. Director, Global Pathogen Safety CSL-Behring on behalf of

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED AND RECOMBINANT COAGULATION FACTOR IX PRODUCTS

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED AND RECOMBINANT COAGULATION FACTOR IX PRODUCTS The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 29 June 2000 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED

More information

Product. Ni-NTA His Bind Resin. Ni-NTA His Bind Superflow. His Bind Resin. His Bind Magnetic Agarose Beads. His Bind Column. His Bind Quick Resin

Product. Ni-NTA His Bind Resin. Ni-NTA His Bind Superflow. His Bind Resin. His Bind Magnetic Agarose Beads. His Bind Column. His Bind Quick Resin Novagen offers a large variety of affinity supports and kits for the purification of recombinant proteins containing popular peptide fusion tags, including His Tag, GST Tag, S Tag and T7 Tag sequences.

More information

Common Inherited Bleeding Disorders

Common Inherited Bleeding Disorders CAA 2015 Annual Conference Common Inherited Bleeding Disorders Bob Miller, A October 8, 2015 VWF has two jobs Loosely bound to protect FVIII and tether to site of injury All other coagulation factors also

More information

Guideline on clinical investigation of recombinant and human plasma-derived factor IX products

Guideline on clinical investigation of recombinant and human plasma-derived factor IX products 21 July 2011 EMA/CHMP/BPWP/144552/2009 Committee for medicinal products for human use (CHMP) Guideline on clinical investigation of recombinant and human plasma-derived factor Draft Agreed by Blood Products

More information

EMA Workshop on Hemophilia Registries. Industry Perspectives

EMA Workshop on Hemophilia Registries. Industry Perspectives EMA Workshop on Hemophilia Registries Industry Perspectives - London Mary Gustafson Vice President Medical and Regulatory Policy Plasma Protein Therapeutics Association Industry Collaborators Thomas Barnett

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE CLINICAL INVESTIGATION OF RECOMBINANT FACTOR VIII AND IX PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE CLINICAL INVESTIGATION OF RECOMBINANT FACTOR VIII AND IX PRODUCTS European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 19 July 2007 CPMP/BPWG/1561/99 rev.1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE

More information

Best Practices in Formulation and Lyophilization Development Proteins, mabs and ADCs

Best Practices in Formulation and Lyophilization Development Proteins, mabs and ADCs Best Practices in Formulation and Lyophilization Development Proteins, mabs and ADCs Best Practices in Formulation and Lyophilization Development The ultimate goal of formulation development is a stable

More information

Note: The taller 100 x 13 mm tube is not designed to run on the ACL TOP. Plasma after centrifugation of these tubes must be placed in sample cups.

Note: The taller 100 x 13 mm tube is not designed to run on the ACL TOP. Plasma after centrifugation of these tubes must be placed in sample cups. Created Revised Reviewed Approved Lupus Insensitive aptt on the ACL TOP HEM 4.15.1 7/13/2012 4/11/2013 4/11/2013 4/11/2013 I. PRINCIPLE The activated partial thromboplastin time is a global screening procedure

More information

Capture of mouse monoclonal antibodies

Capture of mouse monoclonal antibodies Capture of mouse monoclonal antibodies by cation exchange chromatography Life Science Products Processing Capture of mouse monoclonal antibodies from cell culture supernatant by cation exchange chromatography

More information

Mouse IGF-1 ELISA Kit

Mouse IGF-1 ELISA Kit GenWay Biotech, Inc. 6777 Nancy Ridge Drive San Diego, CA 92121 Phone: 858.458.0866 Fax: 858.458.0833 Email: sales@genwaybio.com http://www.genwaybio.com Mouse IGF-1 ELISA Kit Catalog No GWB-ZZD063 Size

More information

Common Inherited Coagulation Disorders. Inherited Coagulation Disorders. All coagulation factors and platelets in circulation (unactivated)

Common Inherited Coagulation Disorders. Inherited Coagulation Disorders. All coagulation factors and platelets in circulation (unactivated) Common Inherited Coagulation Disorders Bob Miller, A 2017 Inherited Coagulation Disorders Brief review of coagulation Disorders related to platelet dysfunction (not the acquired thrombocytopenias) Disorders

More information

Bovine Serum Albumin (BSA) ELISA Kit

Bovine Serum Albumin (BSA) ELISA Kit Instruction Manual No. M-8100 Bovine Serum Albumin (BSA) ELISA Kit Cat. No. 8100, 96 tests For Detection and Quantitation of Residual Bovine Albumin (BSA) in biological solutions For research use only,

More information

Novel Technologies in Plasma Fractionation. Dieter Fassnacht

Novel Technologies in Plasma Fractionation. Dieter Fassnacht Novel Technologies in Plasma Fractionation Dieter Fassnacht Agenda Grifols Overview Grifols Engineering Innovations in - Pooling - Fractionation - Filling Developing new technologies to provide innovative

More information

SensoLyte Anti-alpha-Synuclein Quantitative ELISA Kit (Human/Mouse/Rat) *Colorimetric*

SensoLyte Anti-alpha-Synuclein Quantitative ELISA Kit (Human/Mouse/Rat) *Colorimetric* Catalog # Kit Size SensoLyte Anti-alpha-Synuclein Quantitative ELISA Kit (Human/Mouse/Rat) *Colorimetric* AS-55550 One 96-well strip plate This kit is optimized to detect human/mouse/rat alpha-synuclein

More information

Plasma Fractionation Today and in the Future Plasma Product Biotechnology Meeting

Plasma Fractionation Today and in the Future Plasma Product Biotechnology Meeting Plasma Fractionation Today and in the Future 2013 Plasma Product Biotechnology Meeting 1 What we do matters Dayna and her husband, Brian, are the parents of four wonderful, amazing children, Charlie, Kate,

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of BeneFIX. This scientific discussion has been updated until 1 September 2000. For scientific information

More information

A Quest For Unusual Infusion Stories

A Quest For Unusual Infusion Stories winter 2009 INSIDE Hemophilia and the Military Life page 4 Homework Before You Even Get to College page 10 Transitioning to the College Experience page 12 Off to College page 17 A publication of A Quest

More information

Current laboratory practices in the diagnosis and management of haemophilia

Current laboratory practices in the diagnosis and management of haemophilia Current laboratory practices in the diagnosis and management of haemophilia Marc Jacquemin University of Leuven BSTH 2013 Detection of severe haemophilia A Validation of the FVIII assay for the detection

More information

Challenges in Managing Acute Bleeding in Patients with Hemophilia

Challenges in Managing Acute Bleeding in Patients with Hemophilia Challenges in Managing Acute Bleeding in Patients with Hemophilia Presented as a Webcast at the 47 th ASHP Midyear Clinical Meeting and Exhibition Tuesday, December 4, 2012 Las Vegas, Nevada Planned and

More information

FORMULATION & LYOPHILIZATION CYCLE DEVELOPMENT OF AN ADC

FORMULATION & LYOPHILIZATION CYCLE DEVELOPMENT OF AN ADC FORMULATION & LYOPHILIZATION CYCLE DEVELOPMENT OF AN ADC A Case Study Wendy Saffell-Clemmer Director, R&D Baxter BioPharma Solutions Antibody Drug Conjugates (ADCs) are complex molecules consisting of

More information

Store samples to be assayed within 24 hours at 2-8 C. For long-term storage, aliquot and freeze samples at -20 C. Avoid repeated freeze-thaw cycles.

Store samples to be assayed within 24 hours at 2-8 C. For long-term storage, aliquot and freeze samples at -20 C. Avoid repeated freeze-thaw cycles. Human Retinol Binding Protein 4, RBP4 ELISA Kit Preparation Plate Washing Discard the solution in the plate without touching the side walls. Blot the plate onto paper towels or other absorbent material.

More information

AVB Sepharose High Performance

AVB Sepharose High Performance GE Healthcare Life Sciences Data file 28-927-54 AB Custom designed media AVB Sepharose High Performance AVB Sepharose High Performance is an affinity chromatography medium (resin) designed for the purification

More information

Kogenate FS: antihemophilic factor rfviii-fs

Kogenate FS: antihemophilic factor rfviii-fs DRUG PROFILE Kogenate FS: antihemophilic factor rfviii-fs Jeanne Lusher & Meera Chitlur Author for correspondence Children s Hospital of Michigan, 3901 Beaubien Boulevard, Detroit, MI 48201, USA Tel.:

More information

Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex

Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex Brand Name : BOTO GENIE 1. Introduction : BOTO GENIE (Botulinum Toxin Type A for Injection Ph.Eur)

More information

MATF Antigen Submission Details and Standard Project Deliverables

MATF Antigen Submission Details and Standard Project Deliverables MATF Antigen Submission Details and Standard Project Deliverables What we require when you submit your antigen: Proteins For a recombinant protein target, we require a minimum of 400µg soluble recombinant

More information

HERCEPTIN Vials 60 mg

HERCEPTIN Vials 60 mg Safety Data Sheet HERCEPTIN Vials 60 mg according to Regulation (EU) nr. 1907/2006 SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Product name

More information

GST Fusion Protein Purification Kit

GST Fusion Protein Purification Kit Glutathione Resin GST Fusion Protein Purification Kit Cat. No. L00206 Cat. No. L00207 Technical Manual No. TM0185 Version 01042012 Index 1. Product Description 2. Related Products 3. Purification Procedure

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked

More information

The practical task of monoclonal IgG purification with CHT TM ceramic hydroxyapatite

The practical task of monoclonal IgG purification with CHT TM ceramic hydroxyapatite The practical task of monoclonal IgG purification with CHT TM ceramic hydroxyapatite Pete Gagnon, Jie He, Paul Ng, Julia Zhen, Cheryl Aberin, Heather Mekosh 11th Annual Waterside Conference, Chicago, May

More information

Combining DOE with an empirical approach to improve vaccine formulation development

Combining DOE with an empirical approach to improve vaccine formulation development Engineering Conferences International ECI Digital Archives Vaccine Technology VI Proceedings 6-13-2016 Combining DOE with an empirical approach to improve vaccine formulation development Jill Livengood

More information

The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO

The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO Haemophilia (2016), 22, 487 498 DOI: 10.1111/hae.13013 REVIEW ARTICLE The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO P. COLLINS,* E. CHALMERS,

More information

Guideline on clinical investigation of recombinant and human plasma-derived factor IX products

Guideline on clinical investigation of recombinant and human plasma-derived factor IX products 21 May 2015 EMA/CHMP/BPWP/144552/2009 Rev. 1, Corr. 1 * Committee for medicinal products for human use (CHMP) Guideline on clinical investigation of recombinant and human plasma-derived factor Draft Agreed

More information

Molecular Origins of Recombinant Factor VIII (rfviii) Stabilization with Pluronic F68. Katherine M. Tadehara A PROJECT.

Molecular Origins of Recombinant Factor VIII (rfviii) Stabilization with Pluronic F68. Katherine M. Tadehara A PROJECT. Molecular Origins of Recombinant Factor VIII (rfviii) Stabilization with Pluronic F68 By Katherine M. Tadehara A PROJECT Submitted to Oregon State University University Honors College In partial fulfillment

More information

1. Bloomsbury BBSRC Centre for Structural Biology, Birkbeck College and University College London.

1. Bloomsbury BBSRC Centre for Structural Biology, Birkbeck College and University College London. Purification/Polishing of His-tagged proteins - Application of Centrifugal Vivapure Ion-exchange Membrane Devices to the Purification/Polishing of Histagged Background Multi-milligram quantities of highly

More information

Planova as a Virus Barrier for Biopharmaceutical Plasma Products

Planova as a Virus Barrier for Biopharmaceutical Plasma Products Planova as a Virus Barrier for Biopharmaceutical Plasma Products Tomo Miyabayashi Technical Marketing Bioprocess Division Asahi Kasei Medical Co., Ltd March 9 th, 2016 IPFA ASIA PACIFIC WORKSHOP Taipei

More information

Application Note. Author. Abstract. Biopharmaceuticals. Verified for Agilent 1260 Infinity II LC Bio-inert System. Sonja Schneider

Application Note. Author. Abstract. Biopharmaceuticals. Verified for Agilent 1260 Infinity II LC Bio-inert System. Sonja Schneider Combining small-scale purification and analysis of monoclonal antibodies on one instrument Protein purification with high-volume injection using the Agilent 126 Infinity Bio-inert Quaternary LC System

More information

Healthcare INDEPENDENT RESEARCH. Healthcare

Healthcare INDEPENDENT RESEARCH. Healthcare INDEPENDENT RESEARCH Healthcare t October 2016 Haemophilia: «Stemming the bleed» Healthcare SHIRE PLC BUY FV 6900p Bloomberg SHP LN Reuters SHP.L Price 5176p High/Low 5323/3480p Market cap. GBP46,738m

More information

SYNAGIS (palivizumab) injection, for intramuscular use Initial U.S. Approval: 1998

SYNAGIS (palivizumab) injection, for intramuscular use Initial U.S. Approval: 1998 US-10672 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNAGIS safely and effectively. See full prescribing information for SYNAGIS. SYNAGIS (palivizumab)

More information

AssayMax Human Transferrin ELISA Kit

AssayMax Human Transferrin ELISA Kit AssayMax Human Transferrin ELISA Kit Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com For any questions regarding troubleshooting or performing

More information

Human IgG Antigen ELISA Kit

Human IgG Antigen ELISA Kit Human IgG Antigen ELISA Kit Catalog No: IHUIGGKT Lot No: SAMPLE INTENDED USE This human immunoglobulin G antigen assay is intended for the quantitative determination of total human IgG antigen in serum,

More information

Mouse Factor XII Total ELISA Kit

Mouse Factor XII Total ELISA Kit Mouse Factor XII Total ELISA Kit Catalog No: IMFXIIKT-TOT Lot No: SAMPLE INTENDED USE This mouse coagulation Factor XII antigen assay is intended for the quantitative determination of total Factor XII

More information

APOB (Human) ELISA Kit

APOB (Human) ELISA Kit APOB (Human) ELISA Kit Catalog Number KA1028 96 assays Version: 17 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 Principle of the Assay... 3 General

More information

Developing Robust and Efficient IEX Methods for Charge Variant Analysis of Biotherapeutics Using ACQUITY UPLC H-Class System and Auto Blend Plus

Developing Robust and Efficient IEX Methods for Charge Variant Analysis of Biotherapeutics Using ACQUITY UPLC H-Class System and Auto Blend Plus Developing Robust and Efficient IEX Methods for Charge Variant Analysis of Biotherapeutics Using ACQUITY UPLC H-Class System and Auto Blend Plus Robert Birdsall, Thomas Wheat, and Weibin Chen Waters Corporation,

More information

An effective platform for purification of IgM monoclonal antibodies using Hydroxyapatite

An effective platform for purification of IgM monoclonal antibodies using Hydroxyapatite An effective platform for purification of IgM monoclonal antibodies using Hydroxyapatite Frank Hensel, Patrys, GmbH Pete Gagnon, Validated Biosystems 5th International Conference on Hydroxyapatite and

More information

Sandwich High Sensitivity ELISA kit for Quantitative Detection of Human VEGF in cell culture supernates, serum, and plasma (heparin, EDTA, citrate).

Sandwich High Sensitivity ELISA kit for Quantitative Detection of Human VEGF in cell culture supernates, serum, and plasma (heparin, EDTA, citrate). GenWay Biotech, Inc. 6777 Nancy Ridge Drive San Diego, CA 92121 Phone: 858.458.0866 Fax: 858.458.0833 Email: techline@genwaybio.com http://www.genwaybio.com Human VEGF ELISA Kit Catalog Number: Size: GWB-ZZK029

More information

Haemophilia Registries quantity versus quality

Haemophilia Registries quantity versus quality www.pei.de Haemophilia Registries quantity versus quality The current situation in Europe Christine Keipert Workshop on Haemophilia Registries July 1 st, 2015 Topics From local to global: The current state

More information

Date: September 11, 2017 Reference No.: FDAA17008

Date: September 11, 2017 Reference No.: FDAA17008 Date: September 11, 2017 Reference No.: FDAA17008 VIA WEB Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 SUBJECT: Draft Standardization

More information

2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Active substances Human fibrinogen, Coagulation Factor XIII (human), Aprotinin (bovine)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Active substances Human fibrinogen, Coagulation Factor XIII (human), Aprotinin (bovine) 1. NAME OF THE MEDICINAL PRODUCT 0.5 ml, 1 ml, 3 ml Powders and solvents for sealant. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Qualitative composition Combi-Set I: Active substances Human fibrinogen,

More information

COMPONENT NAME COMPONENT # QUANTITY STORAGE SHELF LIFE FORMAT. Store at 2-8 C. Do not freeze. Store at 2-8 C. Do not freeze.

COMPONENT NAME COMPONENT # QUANTITY STORAGE SHELF LIFE FORMAT. Store at 2-8 C. Do not freeze. Store at 2-8 C. Do not freeze. This document is available at www.stemcell.com/pis EasySep Mouse CD90. Kit II Catalog #89 For processing x 0^9 cells Description Isolate highly purified CD90.+ (Thy.+) cells from mouse splenocytes or other

More information

Key Issues Dialogue: Hemophilia Featuring thought leaders in the hemophilia community. Biotherapies for Life

Key Issues Dialogue: Hemophilia Featuring thought leaders in the hemophilia community. Biotherapies for Life Key Issues Dialogue: Hemophilia Featuring thought leaders in the hemophilia community Biotherapies for Life CSL Behring produces safe, high-quality plasma-derived biotherapies for the treatment of hemophilia

More information